Cholestasis and cholestatic liver diseases;Cholestase et maladies cholestatiques

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 8-9, 2009, Pages 778-788

  Poupon, R ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BILE ACID; BUDESONIDE; CELL NUCLEUS RECEPTOR; CHENODEOXYCHOLIC ACID; CHOLESTEROL; EXENDIN 4; GLUCAGON LIKE PEPTIDE; GLUTATHIONE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; URSODEOXYCHOLIC ACID;

ACTIVE TRANSPORT; BILE; CHOLESTASIS; DRUG TARGETING; DRUG TREATMENT FAILURE; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INFLAMMATION; INTRAHEPATIC CHOLESTASIS; LIVER CELL; LIVER TRANSPLANTATION; MONOGENIC DISORDER; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; SHORT SURVEY; STEROIDOGENESIS; TRANSCRIPTION REGULATION;

ANIMALS; CHOLESTASIS; CHOLESTASIS, INTRAHEPATIC; HUMANS;

EID: 70249139072     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.04.002     Document Type: Short Survey

References (76)

1. Brauer R.W., Leong G.F., and Holloway R.J. Mechanics of bile secretion; effect of perfusion pressure and temperature on bile flow and bile secretion pressure. Am J Physiol 177 (1954) 103-112
2. Sperber I. Secretion of organic anions in the formation of urine and bile. Pharmacol Rev 11 (1959) 109-134
3. Wheeler H.O., and Mancusi-Ungaro P.L. Role of bile ducts during secretin choleresis in dogs. Am J Physiol 210 (1966) 1153-1159
4. Erlinger S., and Dhumeaux D. Mechanisms and control of secretion of bile water and electrolytes. Gastroenterology 66 (1974) 281-304
5. Poupon R.E., and Evans W.H. Biochemical evidence that Na+, K+-ATPase is located at the lateral region of the hepatocyte surface membrane. FEBS Lett 108 (1979) 374-378
6. Nishida T., Gatmaitan Z., Che M., and Arias I.M. Rat liver canalicular membrane vesicles contain an ATP-dependent bile acid transport system. Proc Natl Acad Sci U S A 88 (1991) 6590-6594
7. Hagenbuch B., Stieger B., Foguet M., Lubbert H., and Meier P.J. Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci U S A 88 (1991) 10629-10633
8. Oude Elferink R.P., and Groen A.K. The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. J Hepatol 23 (1995) 617-625
9. Poupon R., Chrétien Y., Poupon R.E., Ballet F., Calmus Y., and Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet 1 (1987) 834-836
10. Poupon R.E., Balkau B., Eschwege E., Poupon R., and UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 324 (1991) 1548-1554
11. Strautnieks S.S., Bull L.N., Knisely A.S., Kocoshis S.A., Dahl N., Arnell H., et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 20 (1998) 233-238
12. Bull L.N., van Eijk M.J., Pawlikowska L., DeYoung J.A., Juijn J.A., Liao M., et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 18 (1998) 219-224
13. de Vree J.M., Jacquemin E., Sturm E., Cresteil D., Bosma P.J., Aten J., et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 95 (1998) 282-287
14. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., et al. Identification of a nuclear receptor for bile acids. Science 284 (1999) 1362-1365
15. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284 (1999) 1365-1368
16. Wang H., Chen J., Hollister K., Sowers L.C., and Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3 (1999) 543-553
17. Rizzo G., Disante M., Mencarelli A., Renga B., Gioiello A., Pellicciari R., et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol 70 (2006) 1164-1173
18. Meier P.J., and Stieger B. Bile salt transporters. Annu Rev Physiol 64 (2002) 635-661
19. Oude Elferink R.P., Paulusma C.C., and Groen A.K. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 130 (2006) 908-925
20. Karpen S.J. Nuclear receptor regulation of hepatic function. J Hepatol 36 (2002) 832-850
21. Olefsky J.M. Nuclear receptor minireview series. J Biol Chem 276 (2001) 36863-36864
22. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., and Gonzalez F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102 (2000) 731-744
23. Cai S.Y., and Boyer J.L. FXR: a target for cholestatic syndromes?. Expert Opin Ther Targets 10 (2006) 409-421
24. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2 (2005) 217-225
25. Wang Y.D., Chen W.D., Wang M., Yu D., Forman B.M., Huang W., et al. X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48 (2008) 1632-1643
26. Yang F., Huang X., Yi T., Yen Y., Moore D.D., and Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 67 (2007) 863-867
27. Modica S., Murzilli S., Salvatore L., Schmidt D.R., and Moschetta A. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res 68 (2008) 9589-9594
28. Xie W., Radominska-Pandya A., Shi Y., Simon C.M., Nelson M.C., Ong E.S., et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A 98 (2001) 3375-3380
29. Staudinger J.L., Goodwin B., Jones S.A., Hawkins-Brown D., MacKenzie K.I., LaTour A., et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 98 (2001) 3369-3374
30. Kliewer S.A., and Willson T.M. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res 43 (2002) 359-364
31. Xie W., Yeuh M.F., Radominska-Pandya A., Saini S.P., Negishi Y., Bottroff B.S., et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci U S A 100 (2003) 4150-4155
32. Wei P., Zhang J., Egan-Hafley M., Liang S., and Moore D.D. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 407 (2000) 920-923
33. Huang W., Zhang J., Chua S.S., Qatanani M., Han Y., Granata R., et al. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci U S A 100 (2003) 4156-4161
34. Zhang J., Huang W., Chua S.S., Wei P., and Moore D.D. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298 (2002) 422-424
35. Peet D.J., Turley S.D., Ma W., Janowski B.A., Lobaccaro J.M., Hammer R.E., et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93 (1998) 693-704
36. Repa J.J., and Mangelsdorf D.J. The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 8 (2002) 1243-1248
37. Fu X., Menke J.G., Chen Y., Zhou G., MacNaul K.L., Wright S.D., et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 276 (2001) 38378-38387
38. Song C., Hiipakka R.A., and Liao S. Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids 65 (2000) 423-427
39. Chatterjee B., Echchgadda I., and Song C.S. Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol 400 (2005) 165-191
40. Ogura M., Nishida S., Ishizawa M., Sakurai K., Shimizu M., Matsuo S., et al. Vitamin D3 Modulates the Expression of Bile Acid Regulatory Genes and Represses Inflammation in Bile Duct-Ligated Mice. J Pharmacol Exp Ther 328 (2009) 564-570
41. Hewison M. Vitamin D and innate immunity. Curr Opin Investig Drugs 9 (2008) 485-490
42. d'Aldebert E., Biyeyeme Bi Mve M.-J., Mergey M., Wendum D., Firrincieli D., Coilly A., et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 136 (2009) 1435-1443
43. Jacquemin E., and Hadchouel M. Genetic basis of progressive familial intrahepatic cholestasis. J Hepatol 31 (1999) 377-381
44. Jansen P.L., and Muller M. The molecular genetics of familial intrahepatic cholestasis. Gut 47 (2000) 1-5
45. Pauli-Magnus C., Stieger B., Meier Y., Kullak-Ublick G.A., and Meier P.J. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol 43 (2005) 342-357
46. Rosmorduc O., Hermelin B., and Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 120 (2001) 1459-1467
47. Fickert P., Fuchsbichler A., Wagner M., Zollner G., Kaser A., Tilg H., et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127 (2004) 261-274
48. Lammert F., Wang D.Q., Hillebrandt S., Geier A., Fickert P., Trauner M., et al. Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology 39 (2004) 117-128
49. Riely C.A., and Bacq Y. Intrahepatic cholestasis of pregnancy. Clin Liver Dis 8 (2004) 167-176
50. Poupon R. Intrahepatic cholestasis of pregnancy: from bedside to bench to bedside. Liver Int 25 (2005) 467-468
51. Sjovall J., and Sjovall K. Steroid sulphates in plasma from pregnant women with pruritus and elevated plasma bile acid levels. Ann Clin Res 2 (1970) 321-337
52. Meng L.J., Reyes H., Palma J., Hernandez I., Ribalta J., and Sjovall J. Profiles of bile acids and progesterone metabolites in the urine and serum of women with intrahepatic cholestasis of pregnancy. J Hepatol 27 (1997) 346-357
53. Trauner M., Fickert P., and Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 27 (2007) 77-98
54. Keitel V., Vogt C., Haussinger D., and Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 131 (2006) 624-629
55. Mullenbach R., Bennett A., Tetlow N., Patel N., Hamilton G., Cheng F., et al. ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut 54 (2005) 829-834
56. Sookoian S., Castano G., Burgueno A., Gianotti T.F., and Pirola C.J. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol 48 (2008) 125-132
57. Van Mil S.W., Milona A., Dixon P.H., Mullenbach R., Geenes V.L., Chambers J., et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133 (2007) 507-516
58. Fava G., Glaser S., Francis H., and Alpini G. The immunophysiology of biliary epithelium. Semin Liver Dis 25 (2005) 251-264
59. Spirli C., Fabris L., Duner E., Fiorotto R., Ballardini G., Roskams T., et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 124 (2003) 737-753
60. Melero S., Spirli C., Zsembery A., Medina J.F., Joplin R.E., Duner E., et al. Defective regulation of cholangiocyte Cl-/HCO3(-) and Na+/H+ exchanger activities in primary biliary cirrhosis. Hepatology 35 (2002) 1513-1521
61. Arenas F., Hervias I., Uriz M., Joplin R., Prieto J., and Medina J.F. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest 118 (2008) 695-709
62. Prieto J., Garcia N., Marti-Climent J.M., Penuelas I., Richter J.A., and Medina J.F. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 117 (1999) 167-172
63. Zollner G., Fickert P., Silbert D., Fuchsbichler A., Marschall H.U., Zatloukal K., et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 38 (2003) 717-727
64. Poupon R., Ping C., Chrétien Y., Corpechot C., Chazouillères O., Simon T., et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol 49 (2008) 1038-1045
65. Salas J.T., Banales J.M., Sarvide S., Recalde S., Ferrer A., Uriarte I., et al. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 134 (2008) 1482-1493
66. Pauli-Magnus C., Kerb R., Fattinger K., Lang T., Anwald B., Kullak-Ublick G.A., et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 39 (2004) 779-791
67. Rosmorduc O., Hermelin B., Boelle P.Y., Poupon R.E., Poupon R., and Chazouillères O. ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 126 (2004) 1220-1222
68. Melum E., Boberg K.M., Franke A., Bergquist A., Hampe J., Schreiber S., et al. Variation in the mdr3 gene influences disease progression in psc patients and disease susceptibility in epistatic interaction with a polymorphism in the ost-α gene. Hepatology 46 (2007) 265A
69. Henckaerts L., Jaspers M., Van Steenbergen W., Vliegen L., Fevery J., Nuytten H., et al. Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis. J Hepatol 50 (2009) 150-157
70. Blanco P.G., Zaman M.M., Junaidi O., Sheth S., Yantiss R.K., Nasser I.A., et al. Induction of colitis in cftr-/- mice results in bile duct injury. Am J Physiol Gastrointest Liver Physiol 287 (2004) G491-G496
71. Karlsen T.H., Lie B.A., Frey Froslie K., Thorsby E., Broome U., Schrumpf E., et al. Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology 131 (2006) 781-787
72. Paumgartner G., and Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36 (2002) 525-531
73. Rodrigues C.M., Fan G., Ma X., Kren B.T., and Steer C.J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 101 (1998) 2790-2799
74. Kurz A.K., Graf D., Schmitt M., Vom Dahl S., and Haussinger D. Tauroursodesoxycholate-induced choleresis involves p38 (MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 121 (2001) 407-419
75. Fickert P., Wagner M., Marschall H.U., Fuchsbichler A., Zollner G., Tsybrovskyy O., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130 (2006) 465-481
76. Alvaro D., and Mancino M.G. New insights on the molecular and cell biology of human cholangiopathies. Mol Aspects Med 29 (2008) 50-57